01—History
Long-Term Debt History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.
- $2.14B
2 older moves run past ±150% (largest +998.4%); point at, tap or drag across the bars to read one.
02—Ledger
Long-Term Debt, period by period
| Period | Scale | Value | Change | Source |
|---|---|---|---|---|
| FY2025 | $2.14B | +42.3% | 10-K | |
| FY2024 | $1.51B | +0.4% | 10-K | |
| FY2023 | $1.50B | −0.5% | 10-K | |
| FY2022 | $1.51B | +91.3% | 10-K | |
| FY2021 | $787.3M | — | 10-K | |
| FY2020 | $0 | −100.0% | 10-K | |
| FY2019 | $383.0M | +998.4% | 10-K | |
| FY2018 | $34.9M | −72.1% | 10-K | |
| FY2017 | $125.1M | −37.2% | 10-K | |
| FY2016 | $199.2M | +612.3% | 10-K | |
| FY2015 | $28.0M | −43.9% | 10-K | |
| FY2014 | $49.9M | +0.2% | 10-K | |
| FY2013 | $49.8M | +67.8% | 10-K | |
| FY2012 | $29.7M | — | 10-K | |
| FY2011 | $0 | — | 10-K |
03—Questions
What is long-term debt?
Long-term debt includes bonds, mortgages, and other borrowings with maturities greater than one year.
What is Halozyme Therapeutics's current long-term debt?
Halozyme Therapeutics (HALO) annual long-term debt for 2025 was $2.14B, a 42.29% increase from 2024. Halozyme Therapeutics long-term debt for the quarter ending September 30, 2026 was $2.94B.
What was Halozyme Therapeutics's long-term debt in 2024?
Halozyme Therapeutics annual long-term debt for 2024 was $1.51B, a 0.44% increase from 2023.
What was Halozyme Therapeutics's long-term debt in 2023?
Halozyme Therapeutics annual long-term debt for 2023 was $1.50B, a 0.45% decline from 2022.
- Company
- Halozyme Therapeutics
- Ticker
- HALO
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)